Production (Stage)
Atossa Therapeutics, Inc.
ATOS
$0.8317
-$0.0382-4.39%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.85% | 12.21% | -19.52% | -2.91% | 24.19% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | -20.00% | -64.29% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -27.63% | -68.35% | 594.35% | -15.51% | -19.27% |
| Change in Net Operating Assets | 112.92% | -8,355.56% | -98.45% | 53.44% | -54.18% |
| Cash from Operations | 15.49% | -48.44% | -4.83% | 3.55% | 15.67% |
| Capital Expenditure | -- | 100.00% | -233.33% | 50.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | -233.33% | 50.00% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -50.98% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -100.00% | -50.98% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -62.09% | 22.65% | -7.35% | 1.47% | 19.22% |